RSV Vaccine Trial Expands Enrollment to Younger Kids

The study will now include toddlers as young as 12 months to test the safety and efficacy of the new vaccine candidate.

Updated on Oct. 28, 2026 in Children’s Health

RSV Vaccine Trial Expands Enrollment to Younger Kids

Live Poll

Should medical research funding prioritize developing pediatric vaccines for seasonal respiratory viruses?

The Gates Foundation has awarded a $5 million grant to Blue Lake Biotechnology to expand the Phase 1/2a clinical trial of its BLB201 vaccine candidate. The study will now enroll children as young as 12 months to evaluate the safety and efficacy of this intranasal approach against RSV.

Why it matters

Expanding the trial to younger toddlers is critical because RSV leads to up to 80,000 hospitalizations in children under five annually in the U.S. This funding allows researchers to investigate whether the vaccine can reduce disease transmission in this vulnerable population.

A Phase 1/2a clinical trial analyzing 111 participants found an interim vaccine efficacy of over 70% for BLB201. These preliminary findings, analyzed through April 2026, support further study, though the research remains in early stages.

The players

Gates Foundation

A global philanthropic organization that funds health initiatives, including vaccine research and disease prevention.

Blue Lake Biotechnology

A biotechnology firm developing innovative vaccine candidates to address respiratory infections.

The details

BLB201 is an intranasal vaccine candidate that utilizes a parainfluenza virus 5 vector, which is not known to cause disease in humans. By encoding the RSV F protein, the vaccine aims to stimulate mucosal, antibody, and cell-mediated immune responses. The study uses an independent committee to analyze unblinded interim data, allowing researchers to refine trial parameters in real time as they expand enrollment to younger age groups.

April 2026: Unblinded interim trial data analysis performed.
October 28, 2026: Grant award and trial expansion announced.
2026-2027 RSV season: Study of BLB201 in toddlers.

Health Landscape

This development represents a significant advancement in the application of PIV5-vector technology for respiratory health. The research builds upon evolving strategies to move beyond current preventative measures by targeting mucosal immune responses directly in toddlers.

While this vaccine remains in clinical trials, families should stay informed about the RSV infection risks that affect up to 80,000 children under five annually in the U.S. It is worth discussing current seasonal preventative options with a pediatrician to understand what is currently available for your child.

The takeaway

RSV remains a significant health threat for young children, contributing to 10,000 annual deaths in the U.S. Families are encouraged to track local RSV activity reports and consult with a primary care physician to discuss standard protective measures appropriate for their child's age.